Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty

Effect of Adductor-Canal-Blockade on High Pain Responders the 1. or 2. Postoperative Day After Total Knee Arthroplasty

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01549704

Enrollment

Registered

2012-03-09

Start date

2012-02-29

Completion date

2012-12-31

Last updated

2013-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain After Total Knee Arthroplasty

Keywords

Total knee arthroplasty, Adductor canal blockade (ACB), High pain responders, US-guided nerve block

Brief summary

The purpose of this study is to determine whether Adductor-Canal-Blockade (ACB) is superior to placebo when it comes to analgetic efficacy in high pain responders after Total Knee Arthroplasty (TKA). High pain responders are defined as patients reporting VAS \> 60 during knee flexion the 1. or 2. day after surgery.

Detailed description

The patients will be included the 1. or 2. day after surgery. All TKA patients will be screened. Those reporting VAS \> 60 during active 45 degrees knee flexion will be asked to participate. Included patients will receive 2xACB (singleshot) first placebo (30ml saline) and then ropivacaine (30ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.

Interventions

DRUGRopivacaine

Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml). Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.

DRUGSaline

please see intervention description for ropivacaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

* TKA within 48 hours and VAS\>60 during active 45 degrees knee flexion despite conventional pain medication. * Informed consent * ASA 1-3 * BMI 18-40

Exclusion criteria

* Unable to communicate in Danish * Allergic reactions toward drugs used in the * Abuse of alcohol/drugs * Unable to cooperate

Design outcomes

Primary

Measure	Time frame
Difference in VAS between ACB and placebo during active 45 degrees knee flexion	45 minutes

Secondary

Measure	Time frame
Difference in mean VAS between the groups during active knee flexion	15, 30, 60, 75 and 90 minutes
Difference in mean VAS between the groups at rest	15, 30, 60, 75 and 90 minutes

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026